The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
about
Oncolytic Viruses: Therapeutics With an Identity CrisisCpG Oligonucleotides as Cancer Vaccine AdjuvantsInnate Immune Memory: The Latest Frontier of AdjuvanticityA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsEndoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccinesA Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Enrichment assessment of multiple virtual screening strategies for Toll-like receptor 8 agonists based on a maximal unbiased benchmarking data set.Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy.Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens.Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.Determinants of activity at human Toll-like receptors 7 and 8: quantitative structure-activity relationship (QSAR) of diverse heterocyclic scaffolds.Biomaterials for nanoparticle vaccine delivery systems.A single naturally occurring 2'-O-methylation converts a TLR7- and TLR8-activating RNA into a TLR8-specific ligandResiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.Induction of potent adaptive immunity by the novel polyion complex nanoparticles.Negative feedback circuit for toll like receptor-8 activation in human embryonic Kidney 293 using outer membrane vesicle delivered bi-specific siRNA.One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure.Insights on the mechanism of action of immunostimulants in relation to their pharmacological potency. The effects of imidazoquinolines on TLR8.Dysregulation of Toll-Like Receptor 7 Compromises Innate and Adaptive T Cell Responses and Host Resistance to an Attenuated West Nile Virus Infection in Old MiceInfluence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine.Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunityBlockade of high mobility group box 1 augments antitumor T-cell response induced by peptide vaccination as a co-adjuvant.Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases.Vaccine technologies: From whole organisms to rationally designed protein assemblies.Basic concepts and recent advances in nanogels as carriers for medical applications.Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral TherapyType I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists.Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.Fusion of foreign T-cell epitopes and addition of TLR agonists enhance immunity against Neospora caninum profilin in cattle.3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.The genetic background influences the cellular and humoral immune responses to vaccines.Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.Blood-stage malaria of Plasmodium chabaudi induces differential Tlr expression in the liver of susceptible and vaccination-protected Balb/c mice.Retrovirus-based Virus-Like Particle Immunogenicity and its Modulation by Toll-Like Receptor Activation.Adjuvant formulations for virus-like particle (VLP) based vaccines.Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12.
P2860
Q26741020-96287B5F-5E79-4A98-A3EB-8170019D2237Q26783826-50E2B1D9-A792-4CA5-999B-A5AE6269B245Q26783968-AD297BF6-DA28-4A39-BEE0-AA8465F21821Q27321020-72D4725E-9C42-45E5-9D08-35BB761EC837Q28084299-0C390F6D-09B1-4459-996D-8A871D44486FQ30401247-C707D1A0-DB8B-4FDE-8E42-3D1800579E6CQ30959752-ED84D267-10EB-44DC-A803-B90091715037Q33659782-8BDBC787-8037-4890-BEDC-BE52F036CDCBQ33729299-408DCB60-0B91-4EB4-BD5F-1ED805B08BE3Q33746872-1C4FAAB9-83FC-4CA2-A0C0-E88267D307B1Q34260736-EADCE5A6-BA12-48E0-A46E-AC881F050526Q34313816-59E2265D-961F-400D-B6A7-E5E343B6C605Q34345012-62CC0074-CEBE-4BB0-BE63-15FF26E28D9BQ35192409-72DAC4F6-F1B4-4394-AEA0-8878BB293003Q35218562-5474EAA2-9DF5-4A64-BB76-A696601E8B82Q35548034-4E552F31-848D-4040-B89A-C922ABB61935Q35707013-6461837A-E7A5-42D0-9239-12DA46D47C8BQ35904895-929F2FF8-96E2-49EE-B3DE-0CB3853A349EQ36122915-691A5B1C-8497-4E14-8539-2607D78ECA99Q36393002-7BC8E4E7-3F89-42A7-8877-7E6B10F1D4C5Q36481466-E38612F5-FF82-473B-9A2E-4E8B8EABE0CCQ36991329-418F9B70-4F04-4DDB-A297-BD1A352B7807Q37254129-36580781-6EB0-4E66-A267-2B5ED3E1F853Q37544372-7845A22A-70CD-42CD-947B-ACA4D8F07F4BQ37746179-1796FD49-D5C7-474A-B689-5CA452D98406Q38259275-AFD85A28-7CA0-4158-84AC-772012F82FDAQ38806558-EFFB8837-9CDF-48A9-9E45-2A45329CEC3FQ38970116-71040942-B47D-4B2D-B6F6-60651BCC288EQ38971085-2A01D48F-F236-4CF9-8FB4-E9B75F8FBB56Q38976179-30945CC3-40C8-46D9-9477-9576AD4F6A12Q39002621-9502ACDD-98DD-4458-B7F9-F7A3B66EB011Q39500713-48A87298-431F-473D-A7BE-EC1CA0C6856CQ39575305-3A4AE8DC-E93B-4C45-B674-F89B6961D3BBQ39620161-A269E4AC-3038-4F8C-8381-C88DC642C3DAQ39638076-24657668-0A9F-4978-B1F8-626B4FE639A9Q39698048-737507A3-B0A1-4766-9777-B5492D3ABB1BQ40063063-506D7EDC-CFB2-4102-918C-AE287241555DQ40088773-AEA8677D-1170-4E41-9209-F7041B54CA5EQ40093469-54238293-408E-42B2-9053-4B0545DCF70EQ41074599-C4EB95D8-5C12-4174-A0F6-FF21AE9A00D7
P2860
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
@en
type
label
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
@en
prefLabel
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
@en
P2860
P1476
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
@en
P2093
John P Vasilakos
Mark A Tomai
P2860
P304
P356
10.1586/14760584.2013.811208
P577
2013-07-01T00:00:00Z